<DOC>
	<DOCNO>NCT00005007</DOCNO>
	<brief_summary>This study determine drug etanercept , also call Enbrel , effective produce maintain remission ( reduction disease symptom ) Wegener 's granulomatosis ( WG ) . Etanercept block action tumor necrosis factor-alpha , substance may involve inflammatory condition WG . Eight clinical center around United States enroll 181 people WG . Patients equal chance receive either etanercept placebo ( inactive treatment ) . We treat patient standard medication WG addition either etanercept placebo . We treat patient taper dos corticosteroid . After patient ' disease control ( remission ) , reduce dosage standard medication low risk side effect associate drug . During study , collect save blood tissue sample patient use sample address medical question , cause WG factor lead disease progression .</brief_summary>
	<brief_title>Etanercept Wegener 's Granulomatosis</brief_title>
	<detailed_description>The Wegener 's Granulomatosis Etanercept Trial ( WGET ) randomize , placebo-controlled clinical trial . A primary objective trial evaluate safety efficacy etanercept ( Enbrel ; Immunex Corporation , Seattle , WA ) induction maintenance disease remission people Wegener 's granulomatosis ( WG ) use conjunction standard medication . A secondary objective develop specimen bank serum , plasma , whole blood , tissue biopsy sample may use address basic question regard etiology , pathophysiology , monitor WG . The trial phase II/III randomize , double-masked , multicenter trial parallel treatment design . We assign patient randomly either etanercept placebo assignment ratio 1:1 . In addition either etanercept placebo , treat patient standard drug regimen WG accord severity disease . We treat limited WG methotrexate corticosteroid , severe WG cyclophosphamide corticosteroid . After patient ' disease control therapy ( i.e. , standard treatment regimen plus either etanercept placebo ) , taper standard medication accord regimen design ensure patient safety , diminish morbidity associate standard medication , test efficacy etanercept sustain disease remission . The principal outcome measure trial number patient two treatment arm achieve sustain remission measure Birmingham Vasculitis Activity Score WG ( BVAS ) . The sample size 181 patient recruit eight clinical center United States . We stratify randomization clinic disease severity ( limited versus severe ) . Every patient enrol BVAS least three , insure unequivocally active disease . We follow randomized patient , regardless whether remain assigned treatment , common closing date trial , define 12 month enrollment last patient . We perform primary analysis intention-to-treat basis .</detailed_description>
	<mesh_term>Granulomatosis Polyangiitis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Minimum weight 40 kg . Diagnosis WG , exclude infection , malignancy , systemic autoimmune disorder , form vasculitis may mimic WG . At least two five modified American College Rheumatology ( ACR ) criteria diagnosis WG . The modified ACR criterion : ( 1 ) nasal oral inflammation , define development painful painless oral ulcer purulent bloody nasal discharge ; ( 2 ) abnormal chest radiograph , define presence nodule , fix infiltrates , cavity ; ( 3 ) active urinary sediment , define microscopic hematuria ( &gt; 5 red blood cell per highpower field ) red blood cell cast ; ( 4 ) granulomatous inflammation biopsy , define histologic change show granulomatous inflammation within wall artery perivascular extravascular area ( artery arteriole ) ; ( 5 ) positive serum ELISA ANCAs ( antineutrophil cytoplasmic antibody ) direct PR3 . Birmingham Vasculitis Activity Score ( BVAS ) score 3 great within 28 day randomization . This may include either presence one major item ( 3 point ) presence three minor item ( 1 point ) . Willingness ability , assistance caregiver necessary , comply treatment followup procedure . Willingness men woman childbearing potential practice adequate method birth control study 3 month afterwards . Willingness limit alcohol consumption one alcoholic drink per week take methotrexate . Willingness refrain breastfeeding study 3 month afterwards . Collection baseline data within 14 day prior randomization . Signed consent statement . Presence active systemic infection . White blood cell count le 4,000/mm cubed platelet count le 120,000/mm cubed . Creatinine great 2.0 mg/dL secondary nonWG cause ( e.g. , hypertensive nephropathy ) patient limited disease . Known acute chronic liver disease . History multiple sclerosis neurological symptom suggest demyelinate syndrome . Current evidence malignancy malignancy diagnose within 5 year study entry . Patients squamous basal cell carcinoma skin may enrol receive curative surgical treatment . Positive serum pregnancy test woman childbearing potential . Previous treatment specific therapy direct tumor necrosis factor , e.g. , etanercept infliximab .</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Wegener 's granulomatosis</keyword>
	<keyword>Vasculitis</keyword>
	<keyword>Etanercept</keyword>
	<keyword>Tumor necrosis factor</keyword>
</DOC>